{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:23:52Z","timestamp":1793301832906,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhep.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:01:21Z","timestamp":1769101281000},"page":"1102-1111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma"],"prefix":"10.1016","volume":"84","author":[{"given":"Adam","family":"Yopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-4124","authenticated-orcid":false,"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-0656","authenticated-orcid":false,"given":"Edward","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Paul","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinshu","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierce Kah-Hoe","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.01.006_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","article-title":"Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection","volume":"69","author":"Chan","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.surg.2019.08.010","article-title":"Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: a multi-institutional analysis of 1,010 patients","volume":"166","author":"Tsilimigras","year":"2019","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.jhep.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdu383","article-title":"Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types","volume":"25","author":"Dal Maso","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.jhep.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.01.006_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jhep.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.jhep.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fon-2020-0162","article-title":"IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","volume":"16","author":"Hack","year":"2020","journal-title":"Future Oncol"},{"issue":"10415","key":"10.1016\/j.jhep.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"The Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jhep.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jhep.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(12)70521-1","article-title":"Adjuvant bevacizumab in colon cancer: where did we go wrong?","volume":"13","author":"Seymour","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.01.006_bib17","article-title":"Strategies to address non-proportional hazards between survival curves - lessons from phase III trials in hepatocellular carcinoma","author":"Mauro","year":"2026843567","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","article-title":"Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice","volume":"80","author":"Cabibbo","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12893-024-02642-6","article-title":"Prognostic significance of early and multiple recurrences after curative resection for hepatocellular carcinoma","volume":"24","author":"Tanemura","year":"2024","journal-title":"BMC Surg"},{"issue":"2","key":"10.1016\/j.jhep.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10147-023-02434-7","article-title":"Predictors for early recurrence beyond up-to-7 or distant metastasis after hepatocellular carcinoma resection: proposal for borderline resectable HCC","volume":"29","author":"Harimoto","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jhep.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/bjs.11464","article-title":"Hepatocellular carcinoma tumour burden score to stratify prognosis after resection","volume":"107","author":"Tsilimigras","year":"2020","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhep.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2147\/JHC.S370212","article-title":"Extending surgical resection for hepatocellular carcinoma beyond Barcelona clinic for liver cancer (BCLC) stage A: a novel application of the modified BCLC staging system","volume":"9","author":"Wee","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"11","key":"10.1016\/j.jhep.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.15683","article-title":"ERS: a simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma","volume":"43","author":"Costentin","year":"2023","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1038\/s41598-021-87782-y","article-title":"A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma","volume":"11","author":"He","year":"2021","journal-title":"Scientific Rep"},{"issue":"11","key":"10.1016\/j.jhep.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1097\/JS9.0000000000001868","article-title":"Metroticket approach in a retrospective cohort study to predict overall survival after surgical resection for hepatocellular carcinoma","volume":"110","author":"Hoang","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.jhep.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jhep.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep4.1923","article-title":"Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies","volume":"6","author":"Reveron-Thornton","year":"2022","journal-title":"Hepatol Commun"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:56:43Z","timestamp":1780592203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0168827826000176"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}